Nanobiotix is trading lower at $43.06, down -5.13%, on August 20, 2026, as biotechnology shares give back gains following Moderna’s historic cancer-vaccine rally.
- Moderna fell 13.0% premarket as investors took profits, reinforcing a sector-wide pullback.
- No fresh company-specific Nanobiotix announcement was identified.
- Broader biotech weakness, rising Treasury yields and softer U.S. equity markets are the clearest explanation for the decline.